このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

小児1型糖尿病におけるTouchCare Nanoの実世界評価 (NANO-KIDS)

2026年11月15日 更新者:Angela Zanfardino,MD、University of Campania Luigi Vanvitelli

小児および思春期の1型糖尿病患者におけるAPGOアルゴリズム搭載TouchCare Nano自動インスリン送達システムの実世界での有効性と安全性:多施設共同観察研究

The goal of this observational study is to evaluate the effectiveness and safety of the TouchCare Nano automated insulin delivery system in children and adolescents with type 1 diabetes during routine clinical care. The study includes an initial six-month period using conventional AutoMode and a planned additional six-month observational extension using the AutoMeal function in a subset of the original participants.

The main questions are:

  • How do glucose levels and insulin delivery change during the first six months of TouchCare Nano use?
  • How do glucose levels and insulin delivery change when participants switch from conventional AutoMode to AutoMeal?
  • How often do severe hypoglycemia and diabetic ketoacidosis occur during follow-up?

In conventional AutoMode, users estimate and enter the carbohydrate content of meals to calculate meal insulin doses. With AutoMeal, users announce the type of meal-breakfast, lunch, dinner, or snack-without routinely entering carbohydrate amounts or manually selecting an insulin dose. The conventional carbohydrate-based bolus calculator remains available when needed.

Treatment decisions, including transition to AutoMeal, are made as part of routine clinical care. Researchers collect glucose sensor data, insulin delivery information, routine clinical measurements, and safety information. Assessments take place at baseline and after 1, 3, and 6 months in the initial phase. Participants who adopt AutoMeal are assessed immediately before the transition and after 3 and 6 months of AutoMeal use.

調査の概要

状態

完了

条件

詳細な説明

This multicentre, prospective, observational study evaluates the real-world effectiveness and safety of the TouchCare Nano automated insulin delivery (AID) system with the APGO algorithm in young people with type 1 diabetes. The study comprises an initial six-month observation period using conventional AutoMode and a planned six-month observational extension using the AutoMeal function in a subset of the original cohort.

Participants were eligible for the initial phase if they were aged 6-18 years, had type 1 diabetes for at least six months, weighed at least 20 kg, and required a total daily insulin dose of at least 10 units, in addition to meeting the other protocol eligibility criteria. Initiation of the system and subsequent treatment decisions occurred within routine clinical care, without study-assigned treatment allocation.

Initial AutoMode phase

Participants were followed for six months after initiation of the TouchCare Nano AID system. In conventional AutoMode, the APGO algorithm automatically adjusts basal insulin delivery and administers correction boluses, while users estimate carbohydrate intake and use the integrated bolus calculator for meal boluses.

Clinical assessments were performed at baseline and after 1, 3, and 6 months. Outcomes included time in range (TIR; 70-180 mg/dL), additional continuous glucose monitoring (CGM) metrics, insulin delivery parameters, HbA1c, anthropometric measurements, and safety events.

Of the 80 participants initially enrolled, 76 completed the initial six-month observation period.

AutoMeal extension

After completing six months of conventional AutoMode use, the 76 participants were offered the opportunity to use AutoMeal during routine clinical care. Forty-eight participants adopted AutoMeal and were included in the six-month extension analysis; 28 continued using conventional AutoMode.

The AutoMeal extension was included in the original ethics committee-approved protocol and covered by the original informed consent. No separate consent process was conducted for this phase.

AutoMeal allows users to announce meals by selecting breakfast, lunch, dinner, or snack, without routinely entering carbohydrate quantities or manually selecting or confirming an insulin dose. Following meal announcement, the system automatically manages prandial insulin delivery, while automated basal modulation and correction boluses remain active. The conventional carbohydrate-based bolus calculator remains available.

Participants and caregivers received instructions to announce meals 15 minutes before food intake. They were advised to use the conventional carbohydrate-based bolus calculator when the estimated carbohydrate content of a meal differed by more than 20% from the individual's usual carbohydrate content for the corresponding meal category.

The glucose target of 110 mg/dL, active insulin time of two hours, and enabled automated correction boluses remained unchanged following transition from AutoMode to AutoMeal.

The extension baseline was the assessment at the end of the initial six-month AutoMode phase, immediately before transition to AutoMeal. Further assessments occurred after 3 and 6 months of AutoMeal use, corresponding to approximately 9 and 12 months after initial AID initiation. CGM and insulin delivery metrics were assessed using data from the 15 days preceding each extension assessment.

The primary outcome of the extension was the change in TIR (70-180 mg/dL) from the extension baseline to six months of AutoMeal use. Additional outcomes included time in tight range (70-140 mg/dL), time above and below range, mean sensor glucose, glucose standard deviation, coefficient of variation, glucose management indicator, HbA1c, and insulin delivery parameters, including total daily insulin dose, basal insulin, automated basal insulin, and automated bolus insulin.

Safety monitoring included severe hypoglycemia requiring assistance from another person and diabetic ketoacidosis throughout follow-up. Routine diabetes education and clinical care continued during both phases.

The study was conducted in accordance with the Declaration of Helsinki and approved by the relevant Ethics Committee. Written informed consent and age-appropriate assent were obtained, as applicable. Final study data collection was completed on October 15, 2026.

研究の種類

観察的

入学 (実際)

80

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Florence、イタリア
        • Department of Diabetology and Endocrinology at the AOU Meyer IRCCS
    • Italy
      • Messina、Italy、イタリア
        • Pediatric Diabetology Unit at the AOU "G. Martino"
      • Naples、Italy、イタリア
        • Centro Regionale di Diabetologia Pediatrica- AOU Univesità degli Studi della Campania "L.Vanvitelli"

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

6年~18年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Children and adolescents with type 1 diabetes receiving routine care at specialized pediatric diabetes centers in Italy and initiating the TouchCare Nano automated insulin delivery system on clinical indication. A subset of the original cohort continued into a planned six-month observational extension using AutoMeal after completing six months of conventional AutoMode use.

説明

Inclusion Criteria:

  • Age 6 to 18 years
  • Diagnosis of type 1 diabetes mellitus for ≥6 months
  • Treatment with insulin therapy (multiple daily injections or continuous subcutaneous insulin infusion) for ≥6 months prior to enrolment
  • Clinical indication for transition to insulin pump therapy according to routine diabetes care
  • Ability of participant and family to understand and comply with study procedures
  • Written informed consent from parent(s) or legal guardian(s), and assent from the participant when applicable

Exclusion Criteria:

  • Diabetic ketoacidosis within the 3 months before enrollment
  • Use of medications known to affect blood glucose levels
  • Body weight less than 20 kilograms
  • Total daily insulin dose less than 10 international units

Eligibility for the AutoMeal extension:

Participation in and completion of the initial six-month observation period using conventional AutoMode.

Voluntary adoption of the AutoMeal function within routine clinical care. The original age eligibility criterion applies to initial enrollment. Participants reaching adulthood during follow-up remained eligible to continue. The extension was covered by the original informed consent; no separate consent process was conducted.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Young people with type 1 diabetes using the TouchCare Nano system

Participants aged 6-18 years at initial enrollment with type 1 diabetes using the TouchCare Nano automated insulin delivery system as part of routine clinical care.

The original cohort included 80 participants, of whom 76 completed six months of follow-up using conventional AutoMode, with carbohydrate-based meal boluses.

At the end of this period, 48 participants voluntarily adopted the AutoMeal function and were followed for an additional six months. AutoMeal allows users to announce the meal type without routinely entering carbohydrate amounts or manually selecting an insulin dose. The remaining 28 participants continued using conventional AutoMode.

For the AutoMeal extension, baseline was defined as the end of the initial six-month AutoMode period, immediately before transition to AutoMeal. Subsequent assessments were performed after 3 and 6 months of AutoMeal use. Treatment decisions were made within routine clinical care, without study-assigned treatment allocation.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Time in Range (70-180 mg/dL) during the initial AutoMode phase
時間枠:Baseline, 1 month, 3 months, and 6 months

Percentage of time that continuous glucose monitoring values are between 70 and 180 mg/dL during the initial six-month period of TouchCare Nano use in conventional AutoMode.

Baseline, 1 month, 3 months, and 6 months
Time in Range (70-180 mg/dL) during the AutoMeal extension
時間枠:Extension baseline and 3 and 6 months after transition to AutoMeal, corresponding to approximately 6, 9, and 12 months after initial TouchCare Nano initiation.

Percentage of time that continuous glucose monitoring values are between 70 and 180 mg/dL, assessed at the extension baseline and after three and six months of AutoMeal use. Changes from the extension baseline are evaluated at both follow-up assessments and expressed in percentage points. The extension baseline corresponds to completion of six months of conventional AutoMode use, immediately before transition to AutoMeal. Each assessment uses CGM data from the preceding 15 days.

Extension baseline and 3 and 6 months after transition to AutoMeal, corresponding to approximately 6, 9, and 12 months after initial TouchCare Nano initiation.

二次結果の測定

結果測定
メジャーの説明
時間枠
Time below normale glucose range (TBR)
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.

TBR is the percentage of time during which glucose values measured by continuous glucose monitoring (CGM) are below 70 mg/dL

Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
Total daily insulin dose delivered by insulin pump
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.

Total amount of insulin administered per day, expressed in units per day (U/day), including both basal and bolus insulin delivery.

Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
Glycated hemoglobin (HbA1c)
時間枠:Initial phase: baseline and 3 and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.

Glycated hemoglobin (HbA1c) reflects the average blood glucose concentration over the preceding 8-12 weeks and is expressed as percentage (%) and mmol/mol.

Initial phase: baseline and 3 and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
Number of severe low blood sugar events
時間枠:Throughout the initial six-month AutoMode phase and the subsequent six-month AutoMeal extension, up to approximately 12 months after TouchCare Nano initiation.

Number of episodes of severe hypoglycaemia requiring assistance from another person to actively administer carbohydrate, glucagon, or other resuscitative actions.

Throughout the initial six-month AutoMode phase and the subsequent six-month AutoMeal extension, up to approximately 12 months after TouchCare Nano initiation.
Time above glucose normal range (TAR)
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.

TAR is the percentage of time during which glucose values measured by continuous glucose monitoring (CGM) exceed 180 mg/dL

Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
Mean sensor glucose
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.

Average interstitial glucose concentration measured by continuous glucose monitoring during the assessment period.

Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
Total daily basal insulin dose delivered by insulin pump
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.

Total daily basal insulin dose delivered by insulin pump, defined as the cumulative background insulin administered through continuous subcutaneous insulin infusion over a 24-hour period (U/day), excluding bolus insulin.

Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
Total daily bolus insulin dose delivered by insulin pump
時間枠:Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.

Total daily bolus insulin dose delivered by insulin pump, defined as the cumulative amount of corrective and meal-related insulin administered through continuous subcutaneous insulin infusion over a 24-hour period (U/day), excluding basal/background insulin

Initial phase: baseline and 1, 3, and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
Body mass index (BMI)
時間枠:Initial phase: baseline and 3 and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.

Body mass index is calculated as weight in kilograms divided by height in meters squared (kg/m²) and reflects overall body weight relative to height.

Initial phase: baseline and 3 and 6 months after TouchCare Nano initiation; AutoMeal extension: extension baseline and 3 and 6 months after transition to AutoMeal.
Number of diabetic ketoacidosis events
時間枠:Throughout the initial six-month AutoMode phase and the subsequent six-month AutoMeal extension, up to approximately 12 months after TouchCare Nano initiation.

Number of episodes of diabetic ketoacidosis defined by hyperglycaemia associated with metabolic acidosis and requiring medical evaluation or hospitalization.

Throughout the initial six-month AutoMode phase and the subsequent six-month AutoMeal extension, up to approximately 12 months after TouchCare Nano initiation.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Angela Zanfardino, MD、University of Campania "L.Vanvitelli"

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年9月5日

一次修了 (実際)

2026年10月15日

研究の完了 (実際)

2026年10月15日

試験登録日

最初に提出

2026年2月7日

QC基準を満たした最初の提出物

2026年2月14日

最初の投稿 (実際)

2026年2月23日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月15日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 0024366/i

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。